The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer.

Michele VigoloCharlotte UrechSebastien LamyGiulia MonticoneJovanny ZabaletaFokhrul HossainDorota WyczechowskaLuis Del ValleRuth M O'ReganLucio MieleRajwinder LehalSamarpan Majumder

Published in: Cancers (2023)

our data indicate that CB-103 is an attractive candidate for clinical investigation in endocrine-resistant, recurrent breast cancers with biomarker-confirmed Notch activity in combination with SERDs and/or CDKis and in TNBCs with biomarker-confirmed Notch activity in combination with taxane-containing chemotherapy regimens.

Keyphrases

cell proliferation
gene expression
big data
locally advanced
radiation therapy
squamous cell carcinoma
mesenchymal stem cells
oxidative stress
bone marrow
deep learning
artificial intelligence
childhood cancer
chemotherapy induced